Bulletin from Artimplant AB's Annual Meeting of Stockholders 2013

Adoption of financial statements, disposition of result and discharge of
directors and officers
The financial statements of 2012 for the group and the parent company were
adopted. The Annual Meeting decided that the Parent Company’s retained loss of
SEK 8,125,101 will be carried forward and that no dividend will be paid. The
directors and officers of the Company were granted discharge.

Election of Board members and auditor
Board members John Arnold, Rickard Brånemark, Lars Peterson, Håkan Johansson and
Anders Strid were reelected as Board members and Håkan Johansson was elected as
chairman of the Board.

Ernst & Young AB, with Björn Grundvall as responsible auditor, was elected for a
four year period at the AGM 2010 and remains until AGM 2014.

Adoption of fees
The Annual Meeting decided that the fee to the Board of Directors shall be the
same as previous year, SEK 240,000 (240,000) to the chairman and SEK 120,000
(120,000) to ordinary Board members. It was also decided that the fee to the
chairman of the audit committee shall be SEK 20,000 (20,000) and the fee to the
other members shall be SEK 10,000 (10,000). It was decided that no remuneration
committee is necessary. The audit fee will the upcoming year be in accordance
with the existing agreement for audit services, SEK 200,000 per year.

Election committee
The Annual Meeting decided that the election committee before the Annual Meeting
2014, shall be appointed by representatives from the three largest stockholders,
according to voting power, as of September 30, 2013.

Principles for remuneration to senior management
The Annual Meeting adopted the principles for remuneration to senior management
as suggested by the Board of Directors.

All above decisions were taken unanimously.

For additional information, please contact:

Kjell Thörnbring, CEO, phone +46 (0)703 11 90 25,
kjell.thornbring@artimplant.com

Further information is available at www.artimplant.com. To subscribe to future
press releases please go to www.artimplant.com/investors-media/subscribe-to
-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet, for shoulder and other soft
tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on June 28, 2013 at 8:45 AM (CET).